3D Systems has secured U.S. Food and Drug Administration (FDA) 510(k) clearance for expanded indications to its VSP Orthopedics virtual surgical planning and patient-specific instrumentation platform. The planning tool now includes skeletally mature adolescents of normal bone stature, besides adults.

Key investment highlights include:

• Immediate commercial acceleration: Eliminates case-by-case compassionate-use approvals and hospital IRB reviews previously required for these adolescent patients, thereby streamlining workflows and converting off-label usage into standard, reimbursable procedures.
•  Targets high-acuity, underserved segment:
  • More than 1,200 new annual U.S. cases of osteosarcoma and Ewing sarcoma in patients under 20 (American Cancer Society, SEER estimates).
  • Additional 2,600 primary bone cancer cases in young adults (20–39) now fully in-scope.
  • Thousands of complex lower-limb osteotomies and reconstructive procedures annually for congenital, developmental, and trauma-related deformities in adolescents.
•  Strong, sustainable financial model: VSP Orthopedics cases generate service fees for virtual planning combined with revenue from patient-specific 3D-printed anatomic models and single-use surgical guides produced on 3D Systems’ additive manufacturing platforms. Resulting revenues contribute to the strong, double-digit annual growth rates and highly accretive gross margins associated with 3D Systems’ Med Tech business.
•  Strengthened competitive moat: 3D Systems is the only provider with FDA-cleared VSP solutions spanning craniomaxillofacial, orthopedics, and now expanded adolescent applications, with more than 400,000 total patient-matched cases and devices delivered to date.
•  Favorable reimbursement: Procedures covered under existing DRG/CPT codes for tumor resection, osteotomy, and reconstruction—no changes required.

“This regulatory clearance removes a significant friction point for adoption in the pediatric/adolescent orthopedic oncology segment,” said Ben Johnson, senior vice president of medical technology at 3D Systems. “Surgeons have been using off-label or compassionate use solutions for years; this decision immediately converts those cases into routine clinical practice and opens the U.S. adolescent bone sarcoma and deformity market to our platform. We are thrilled to now offer these solutions to an expanded and underserved patient population.”

This regulatory clearance further supports 3D Systems’ focus on high-margin personalized healthcare solutions amid ongoing segment optimization efforts. Continuing expanded indications provides a meaningful tailwind for sustaining double-digit average annual growth in the healthcare segment, driven in part by accelerated adoption in this discrete, high-value market.

For nearly 40 years, Chuck Hull’s curiosity and desire to improve the way products were designed and manufactured gave birth to 3D printing, 3D Systems, and the additive manufacturing industry. Since then, that same spark continues to ignite the 3D Systems team as it works with customers to change the way industries innovate. As a full-service solutions partner, the firm delivers 3D printing technologies, materials, and software to high-value markets such as medical and dental; aerospace, space and defense; transportation and motorsports; AI infrastructure; and durable goods.